Treatment with SR18662 considerably lowers development and proliferation of CRC cells. SR18662 displays enhanced efficacy in cutting down viability of various CRC cell lines. Circulation cytometry Examination following SR18662 treatment exhibits an increase in cells captured in either S or G2/M phases on the mobile cycle and a major rise https://freemanf296wcg0.blogdemls.com/profile